Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ji Xing Pharma In-licenses China Rights to Heart Drug in $425 Million Deal

publication date: Jul 15, 2020

Ji Xing Pharma of Shanghai in-licensed China rights to a cardiac myosin inhibitor from South San Francisco-based Cytokinetics in a deal worth up to $425 million. CK-274 is a potential treatment for hypertrophic cardiomyopathy, Ji Xing will make an unspecified upfront payment and pay up to $200 million in milestones plus royalties on sales. RTW Investments, a New York backer of Ji Xing, will purchase $50 million in Cytokinetics' equity and provide up to $90 million to develop CK-274. Also, RTW has agreed to buy royalty rights to CK-274 for $85 million. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital